Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease

scholarly article by Ariel Gordin & David J. Brooks published August 2007 in Journal of Neurology

Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00415-007-4007-9

P2093author name stringDavid J. Brooks
Ariel Gordin
P2860cites workCOMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?Q35626734
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's diseaseQ39112092
Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysisQ43797164
COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's diseaseQ43896022
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patientsQ48125712
Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral InhibitorQ51107835
Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease.Q54002951
P433issueS4
P921main subjectParkinson's diseaseQ11085
pharmacologyQ128406
P304page(s)IV37-IV48
P577publication date2007-08-01
P1433published inJournal of NeurologyQ6295649
P1476titleClinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease
P478volume254

Reverse relations

Q45934197Levodopa/carbidopa/entacapone in Parkinson's disease.cites workP2860

Search more.